RNA, U6 small nuclear 263, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-263P profile across patient tissues and cancer cell-line models. RNU6-263P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RNU6-263P is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, RNU6-263P RNA expression shows 6,187 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CESC, THCA, and STAD as cancer lineages where RNU6-263P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-263P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-263P survival associations across molecular data types. RNU6-263P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-263P RNA expression–survival associations across cancer types. High RNU6-263P expression shows unfavorable associations in CESC, STAD, THCA, BLCA, LIHC and KIRC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for RNU6-263P RNA expression.
This table summarizes RNU6-263P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-263P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-263P shows lower tumor expression in THCA. The THCA box plot shows higher RNU6-263P RNA expression in normal versus tumor tissue (log2 FC = −0.256, t-test p = .006).
This table shows molecular features associated with RNU6-263P in patient tissues and cancer cell lines. In patient samples, RNU6-263P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
